1 February 2023 in Circulation: Heart Failure
Background: Guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) improves clinical outcomes and quality of life. Optimizing GDMT in the hospital is associated with greater long-term use in HFrEF. This study aimed to describe the efficacy of a multidisciplinary virtual HF intervention on GDMT optimization among patients with HFrEF admitted for any cause. Methods: In this pilot randomized, controlled study, consecutive patients with HFrEF admitted to noncardiology medicine services for any cause were identified at a large academic tertiary care hospital between May to September 2021. Major exclusions were end-stage renal disease, hemodynamic instability, concurrent COVID-19 infection, and current enrollment in hospice care. Patients were randomized to a clinician-level virtual peer-to-peer consult intervention providing GDMT recommendations and information on medication costs versus usual care. Primary end points included (1) proportion of patients with new GDMT initiation or use and (2) changes to HF optimal medical therapy scores which included target dosing (range, 0–9). Results: Of 242 patients identified, 91 (38%) were eligible and randomized to intervention (N=52) or usual care (N=39). Baseline characteristics were similar between intervention and usual care (mean age 63 versus 67 years, 23% versus 26% female, 46% versus 49% Black, mean ejection fraction 33% versus 31%). GDMT use on admission was also similar. There were greater proportions of patients with GDMT initiation or continuation with the intervention compared with usual care. After adjusting for optimal medical therapy score on admission, changes to optimal medical therapy score at discharge were higher for the intervention group compared with usual care (+0.44 versus −0.31, absolute difference +0.75, adjusted estimate 0.86±0.42; P =0.041). Conclusions: Among eligible patients with HFrEF hospitalized for any cause on noncardiology services, a multidisciplinary pilot virtual HF consultation increased new GDMT initiation and dose optimization at discharge.
19 February 2010 in PLOS ONE
ABAdelia Portero Batilana
+3
Sharing of epidemiological and clinical data sets among researchers is poor at best, in detriment of science and community at large. The purpose of this paper is therefore to (1) describe a novel Web application designed to share information on study data sets focusing on epidemiological clinical research in a collaborative environment and (2) create a policy model placing this collaborative environment into the current scientific social context. The Database of Databases application was developed based on feedback from epidemiologists and clinical researchers requiring a Web-based platform that would allow for sharing of information about epidemiological and clinical study data sets in a collaborative environment. This platform should ensure that researchers can modify the information. A Model-based predictions of number of publications and funding resulting from combinations of different policy implementation strategies (for metadata and data sharing) were generated using System Dynamics modeling. The application allows researchers to easily upload information about clinical study data sets, which is searchable and modifiable by other users in a wiki environment. All modifications are filtered by the database principal investigator in order to maintain quality control. The application has been extensively tested and currently contains 130 clinical study data sets from the United States, Australia, China and Singapore. Model results indicated that any policy implementation would be better than the current strategy, that metadata sharing is better than data-sharing, and that combined policies achieve the best results in terms of publications. Based on our empirical observations and resulting model, the social network environment surrounding the application can assist epidemiologists and clinical researchers contribute and search for metadata in a collaborative environment, thus potentially facilitating collaboration efforts among research communities distributed around the globe.
1 May 2025 in Digital Health
Artificial intelligence (AI) is reshaping healthcare, influencing everything from administrative workflows to direct patient care. It holds promise in addressing the leading cause of death in the United States and a significant driver of costs – cardiovascular disease (CVD). Traditional reimbursement models are slow to incorporate AI. This article explores alternative financial incentives for AI in CVD prevention in fee-for-service (FFS) and value-based care models across four domains – risk prediction, diagnostics, imaging, clinical decision support, and administrative strategies – where AI may provide indirect revenue generation, cost savings, and efficiency gains. Under FFS, AI can enhance revenue by driving appropriate healthcare utilization, improving billing accuracy, and streamlining administrative workflows. In value-based models, AI aligns with incentives to prevent disease progression, reduce hospitalizations, and optimize shared savings. While AI-powered tools offer a compelling financial value proposition in cardiovascular prevention, their real-world adoption and impact will depend on successful clinical validation and seamless integration into existing workflows. The future of AI in cardiovascular care depends on a shift in reimbursement models, regulatory adaptation, and continued evidence generation demonstrating cost-effectiveness and improved outcomes. As healthcare transitions toward value-based care, AI has the potential to be a catalyst for better prevention and long-term cost savings, but only if its business case is strategically developed and implemented.
1 November 2021 in The American Journal of Cardiology
25 January 2026 in Journal of Human Hypertension
1 January 2022 in The World Journal of Men's Health
FSfor the Duke Cancer Institute Planning Committee for Prostate Cancer Screening
for the Duke Cancer Institute Planning Committee for Prostate Cancer Screening
+11
Michael ZD, et al. World J Mens Health. 2022 Aug;40:e60. https://doi.org/10.5534/wjmh.220068